Hester Biosciences, a company in the Pharmaceuticals industry, reported revenue of ₹98 crore and net profit of ₹21 crore for the September 2026 quarter.
Hester Biosciences (NSE: HESTERBIO) closed at ₹2,329.90 on 20 Nov 2026, up 37.4% over the past year. Its market capitalisation is ₹1,982 crore and it trades at 33.8 times earnings.
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.